VANCOUVER, British Columbia (AP) _ Novelion Therapeutics Inc. (NVLN) on Thursday reported a loss of $19.4 million in its fourth quarter.
On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.03. Earnings, adjusted for non-recurring costs and stock option expense, were 15 cents per share.
The retinal disease treatment developer posted revenue of $40.7 million in the period.
For the year, the company reported that its loss narrowed to $108.3 million, or $5.76 per share. Revenue was reported as $130.4 million.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVLN at https://www.zacks.com/ap/NVLN